Aktuellt
SENASTE
We welcome the transparency and a firm set of clear goals ahead of 2022 from Hansa Biopharma (Hansa). These also include preliminary top-line Q4 results. Despite Omicron, most of the clinical targets remain in a place subject to restrictions. Q4 is now including some early support from European Idefirix product sales and the intention to explore the opportunity to use Imlifidase as a stem cell transplant enabler in the HSCT segment. Hansa points to 2022 as a year of considerable progress ahead of a potentially transformative 2023.
LÄS MER
